免疫检查点抑制剂相关暴发性心肌炎的临床和病理特征

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardio-oncology Pub Date : 2024-11-21 DOI:10.1186/s40959-024-00288-0

Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe

{"title":"免疫检查点抑制剂相关暴发性心肌炎的临床和病理特征","authors":"Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe","doi":"10.1186/s40959-024-00288-0","DOIUrl":null,"url":null,"abstract":"The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"10 1","pages":"82"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580468/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis.\",\"authors\":\"Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe\",\"doi\":\"10.1186/s40959-024-00288-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.\",\"PeriodicalId\":9804,\"journal\":{\"name\":\"Cardio-oncology\",\"volume\":\"10 1\",\"pages\":\"82\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardio-oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40959-024-00288-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00288-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

免疫检查点抑制剂（ICIs）的出现大大改善了癌症治疗。随着 ICIs 的使用越来越多，ICI 相关性心肌炎也被人们所认识。然而，由于对 ICI 相关心肌炎的了解有限，基于证据的治疗策略尚未确立。在此，我们介绍了四例与 ICI 相关的暴发性心肌炎（FM）病例。尽管患者接受了机械循环支持和皮质类固醇免疫抑制治疗，但四例病例中有三例最终死亡。鉴于 ICI-FM 的预后较差，根据临床和病理评估建立快速、适当的治疗干预措施势在必行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis.

The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cardio-oncology Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.00

自引率

3.00%

发文量

审稿时长

7 weeks